164 related articles for article (PubMed ID: 28165374)
1. Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Stammes MA; Prevoo HA; Ter Horst MC; Groot SA; Van de Velde CJ; Chan AB; de Geus-Oei LF; Kuppen PJ; Vahrmeijer AL; Pasquale EB; Sier CF
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28165374
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer.
de Muijnck C; van Gorkom Y; van Duijvenvoorde M; Eghtesadi M; Dekker-Ensink G; Bhairosingh SS; Affinito A; Kuppen PJK; Vahrmeijer AL; Sier CFM
Pharmaceuticals (Basel); 2020 Jul; 13(8):. PubMed ID: 32751634
[TBL] [Abstract][Full Text] [Related]
3. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.
Brantley-Sieders DM; Jiang A; Sarma K; Badu-Nkansah A; Walter DL; Shyr Y; Chen J
PLoS One; 2011; 6(9):e24426. PubMed ID: 21935409
[TBL] [Abstract][Full Text] [Related]
4. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne PD; Dasgupta S; Blayney JK; McArt DG; Redmond KL; Weir JA; Bradley CA; Sasazuki T; Shirasawa S; Wang T; Srivastava S; Ong CW; Arthur K; Salto-Tellez M; Wilson RH; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2016 Jan; 22(1):230-242. PubMed ID: 26283684
[TBL] [Abstract][Full Text] [Related]
5. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.
Saito T; Masuda N; Miyazaki T; Kanoh K; Suzuki H; Shimura T; Asao T; Kuwano H
Oncol Rep; 2004 Mar; 11(3):605-11. PubMed ID: 14767510
[TBL] [Abstract][Full Text] [Related]
6. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
7. Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells.
Dimasi N; Fleming R; Hay C; Woods R; Xu L; Wu H; Gao C
Mol Pharm; 2015 Sep; 12(9):3490-501. PubMed ID: 26176328
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between the Tissue Factor/coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer.
Eriksson O; Thulin Å; Asplund A; Hegde G; Navani S; Siegbahn A
BMC Cancer; 2016 May; 16():341. PubMed ID: 27246245
[TBL] [Abstract][Full Text] [Related]
9. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer.
Kataoka H; Igarashi H; Kanamori M; Ihara M; Wang JD; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Maruyama K; Nakamura T; Arai H; Kajimura M; Hanai H; Tanaka M; Sugimura H
Cancer Sci; 2004 Feb; 95(2):136-41. PubMed ID: 14965363
[TBL] [Abstract][Full Text] [Related]
10. EphA2 as a phase separation protein associated with ferroptosis and immune cell infiltration in colorectal cancer.
Li Y; Peng Q; Wang L
Aging (Albany NY); 2023 Nov; 15(22):12952-12965. PubMed ID: 37980165
[TBL] [Abstract][Full Text] [Related]
11. Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer.
Tröster A; Jores N; Mineev KS; Sreeramulu S; DiPrima M; Tosato G; Schwalbe H
ChemMedChem; 2023 Dec; 18(23):e202300420. PubMed ID: 37736700
[TBL] [Abstract][Full Text] [Related]
12. EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
Lv J; Xia Q; Wang J; Shen Q; Zhang J; Zhou X
Exp Mol Pathol; 2016 Jun; 100(3):402-8. PubMed ID: 27072105
[TBL] [Abstract][Full Text] [Related]
13. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis.
Herath NI; Spanevello MD; Doecke JD; Smith FM; Pouponnot C; Boyd AW
Eur J Cancer; 2012 Mar; 48(5):753-62. PubMed ID: 21852108
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.
De Robertis M; Loiacono L; Fusilli C; Poeta ML; Mazza T; Sanchez M; Marchionni L; Signori E; Lamorte G; Vescovi AL; Garcia-Foncillas J; Fazio VM
Clin Cancer Res; 2017 Jan; 23(1):159-170. PubMed ID: 27401248
[TBL] [Abstract][Full Text] [Related]
15. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
Ireton RC; Chen J
Curr Cancer Drug Targets; 2005 May; 5(3):149-57. PubMed ID: 15892616
[TBL] [Abstract][Full Text] [Related]
16. Engineering of an EPHA2-Targeted Monobody for the Detection of Colorectal Cancer.
Venu A; Zhang Y; Seong J; Hong Y; Lee WS; Min JJ
Cancer Genomics Proteomics; 2024; 21(3):285-294. PubMed ID: 38670584
[TBL] [Abstract][Full Text] [Related]
17. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.
Posthumadeboer J; Piersma SR; Pham TV; van Egmond PW; Knol JC; Cleton-Jansen AM; van Geer MA; van Beusechem VW; Kaspers GJ; van Royen BJ; Jiménez CR; Helder MN
Br J Cancer; 2013 Oct; 109(8):2142-54. PubMed ID: 24064975
[TBL] [Abstract][Full Text] [Related]
18. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
19. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.
Toma MI; Erdmann K; Diezel M; Meinhardt M; Zastrow S; Fuessel S; Wirth MP; Baretton GB
PLoS One; 2014; 9(7):e102262. PubMed ID: 25025847
[TBL] [Abstract][Full Text] [Related]
20. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
